Insofar as many studies (Fink and Cookson, 2005; Kobayashi et al., 2013; Li et al., 2016; Tonnus et al., 2019) associate the inhibitory effect that minocycline may have on caspase-1, NLRP-3 and TLR-4, and the phenotype M1, it should be stressed that the disruption of these pathways seems detrimental in DCS, even though it is necessary to remain prudent about the degree of involvement of this innate immunity pathway in DCS, because its blockage by minocycline did not result in a notable increase in the number of cases of DCS. This evidence concerns the gene NLRP3 and Dorfman-Chanarin disease.